Genetic Technologies Limited (GENE) Balance Sheet

OTC Pink: GENEAssets, liabilities, debt and equity over 10 years.

GENE balance sheet, FY2024

June 30, 2024 · Australian dollars

A$6.2M assets = A$4.4M liabilities + A$1.8M equity

What it ownsA$6.2MCash & ST investments: A$1.0M (16.5%)Cash & ST investmentsA$1.0M · 16%Receivables: A$2.1M (34.4%)ReceivablesA$2.1M · 34%Inventory: A$206,468 (3.3%)Other current: A$341,746 (5.5%)PP&E: A$264,491 (4.3%)Goodwill & intangibles: A$2.1M (34.7%)Goodwill & intangiblesA$2.1M · 35%Other non-current: A$81,698 (1.3%)=How it is financedA$6.2MCurrent liabilities: A$4.2M (67.8%)Current liabilitiesA$4.2M · 68%Other LT liabilities: A$160,643 (2.6%)Shareholders’ equity: A$1.8M (29.6%)Shareholders’ equityA$1.8M · 30%

Both columns are drawn to the same scale: what GENE owns equals what it owes plus shareholders’ equity. Hover a block for its value.

GENE financial health

Current ratio0.88
Tight · current assets cover current liabilities 0.88×
Debt / equity0.48
Low leverage · A$0.48 of debt for each $1 of equity
Equity / assets29.6%
Balanced · of assets funded by shareholders
Cash / debt116.6%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles34.7%
Acquisition-heavy · of total assets

Descriptive bands, not a rating. Fiscal FY2024.

GENE balance sheet trends, FY2015–FY2024

Genetic Technologies Limited balance sheet trends
MetricTrendThenLatestChange
Total assetsA$20.7MFY2015A$6.2MFY2024−12.6%/yr
Total liabilitiesA$1.8MFY2015A$4.4MFY2024+10.6%/yr
Shareholders’ equityA$19.0MFY2015A$1.8MFY2024−22.9%/yr
Cash & short-term investmentsA$18.3MFY2015A$1.0MFY2024−27.5%/yr
Total debtA$25,000FY2015A$875,189FY2024+48.4%/yr
Net cash (debt)A$18.3MFY2015A$145,419FY2024−A$18.2M
Working capitalA$17.8MFY2015−A$500,088FY2024−A$18.3M
Current ratio11.28FY20150.88FY2024−10.40
Debt / equity0.00FY20150.48FY2024+0.48
Shares outstanding358KFY20154.6MFY2024+32.9%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

GENE assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

GENE liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

GENE debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

GENE balance sheet in Australian dollars

Genetic Technologies Limited annual balance sheet
FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Assets
Cash & short-term investmentsA$1.0MA$7.9MA$11.7MA$20.9MA$14.2MA$2.2MA$5.5MA$11.0MA$11.2MA$18.3M
Cash & equivalentsA$1.0MA$7.9MA$11.7MA$20.9MA$14.2MA$2.1MA$5.5MA$11.0MA$11.2MA$18.3M
Short-term investmentsA$18,790A$17,440A$13,257A$1,856A$2,025A$53,456A$3,505A$3,377A$4,209A$3,590
ReceivablesA$2.1MA$191,903A$2.4MA$1.1MA$38,871A$16,529A$10,503A$200,837A$392,521A$524,580
InventoryA$206,468A$325,893A$398,150A$76,927A$91,390A$31,864A$59,007A$76,822A$166,942A$317,497
Other current assetsA$341,746A$2.1MA$166,087A$182,580A$846,303A$962,082A$430,647A$362,358A$387,711A$379,072
Total current assetsA$3.7MA$10.5MA$14.7MA$22.2MA$15.2MA$3.2MA$6.0MA$11.6MA$12.1MA$19.6M
Property, plant & equipment (net)A$264,491A$599,176A$953,325A$637,706A$440,230A$69,333A$175,284A$476,648A$550,139A$417,595
Goodwill & intangible assetsA$2.1MA$3.6MA$5.1MA$9.6MA$0A$0A$0A$0A$608,477A$736,041
Long-term investmentsA$0A$0A$0A$0A$0A$0A$0A$0A$0A$0
Other non-current assetsA$81,698A$121,901A$0A$0A$0A$0A$0A$0A$0A$0
Total assetsA$6.2MA$14.9MA$20.8MA$23.0MA$15.6MA$3.3MA$6.2MA$12.1MA$13.3MA$20.7M
Liabilities
Accounts payableA$1.5MA$837,952A$1.2MA$269,665A$350,151A$590,231A$535,924A$398,291A$392,322A$517,078
Short-term debtA$852,265A$303,570A$264,130A$179,626A$240,915A$0A$0A$0A$0A$25,000
Deferred revenueA$741,647A$849,212A$814,150A$635−A$240,915————A$77,282
Total current liabilitiesA$4.2MA$3.3MA$3.8MA$1.4MA$1.4MA$1.5MA$1.5MA$1.5MA$1.3MA$1.7M
Long-term debtA$0A$0A$0A$0A$52,252A$0A$0A$0A$0A$0
Lease obligationsA$231,643A$532,846A$652,526A$204,038A$429,536A$0A$0A$0A$0A$0
Other long-term liabilitiesA$160,643A$381,616A$558,908A$33,272A$0A$809A$2.5MA$63,960A$74,308A$25,321
Total liabilitiesA$4.4MA$3.7MA$4.4MA$1.4MA$1.6MA$1.5MA$1.5MA$1.5MA$1.4MA$1.8M
Shareholders' equity
Common stock & paid-in capitalA$163.8MA$161.3MA$155.1MA$153.6MA$140.1MA$125.5MA$122.4MA$122.4MA$115.3MA$115.2M
Retained earnings (deficit)−A$166.4M−A$156.7M−A$150.2M−A$143.1M−A$136.0M−A$129.7M−A$123.3M−A$117.8M−A$109.4M−A$101.0M
Treasury stock—————A$0A$0A$0A$0A$0
Accumulated other comprehensive incomeA$4.4MA$6.5MA$11.5MA$11.0MA$9.9MA$6.0MA$5.7MA$6.0MA$6.1MA$4.7M
Minority interest—————A$0A$0A$0A$0A$0
Total shareholders' equityA$1.8MA$11.2MA$16.4MA$21.5MA$14.0MA$1.8MA$4.7MA$10.6MA$11.9MA$19.0M
Key figures
Total debtA$875,189A$532,846A$652,526A$204,038A$481,788A$0A$0A$0A$0A$25,000
Net cash (debt)A$145,419A$7.3MA$11.1MA$20.7MA$13.7MA$2.2MA$5.5MA$11.0MA$11.2MA$18.3M
Working capital−A$500,088A$7.2MA$10.9MA$20.8MA$13.8MA$1.7MA$4.5MA$10.2MA$10.8MA$17.8M
Tangible book value−A$314,542A$7.5MA$11.3MA$11.9MA$14.0MA$1.8MA$4.7MA$10.6MA$11.3MA$18.2M
Shares outstanding4.6M3.4M3.1M2.8M1.4M941K812K707K572K358K
Current ratio0.883.173.8615.8210.872.144.137.949.1111.28
Quick ratio0.752.433.7115.6410.201.473.797.648.6910.87
Debt / equity0.480.050.040.010.030.000.000.000.000.00
Equity / assets29.6%75.1%79.0%93.7%89.5%54.2%76.4%87.4%89.4%91.5%

Quarterly columns are labeled by the month the quarter ended. Figures in Australian dollars as reported (latest annual report filed June 30, 2024); data from EODHD.

GENE financial position

At the end of fiscal 2024 (June 30, 2024), Genetic Technologies had total assets of A$6.2 million (down 58.4% from a year earlier), total liabilities of A$4.4 million and shareholders' equity of A$1.8 million. It held A$1.0 million in cash and short-term investments against A$0.9 million of debt, a net cash position of A$0.1 million. Its current ratio was 0.88.

Related: GENE income statement, GENE cash flow statement, GENE key metrics. See the GENE stock overview for the latest quote and news.

GENE balance sheet FAQ

What are Genetic Technologies's total assets?

Genetic Technologies reported total assets of A$6.2 million at the end of fiscal 2024 (June 30, 2024), compared with A$14.9 million a year earlier.

How much debt does Genetic Technologies have?

Genetic Technologies had A$0.9 million of total debt at the end of fiscal 2024, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.48.

How much cash does Genetic Technologies have?

Genetic Technologies held A$1.0 million in cash and short-term investments at the end of fiscal 2024; with A$0.9 million of debt that is net cash of A$0.1 million.

What is Genetic Technologies's book value?

Genetic Technologies's shareholders' equity (book value) was A$1.8 million at the end of fiscal 2024.

What is Genetic Technologies's current ratio?

Genetic Technologies had current assets of A$3.7 million and current liabilities of A$4.2 million, a current ratio of 0.88 (current liabilities exceed current assets).

How much goodwill does Genetic Technologies have?

Genetic Technologies carried A$2.1 million of goodwill and intangible assets, 34.7% of total assets, at the end of fiscal 2024.

Diagnostics & Research: balance sheet